[Molecular farming has come of age].
Important development in plant biotechnology has been ushered in the 1990s, the most astounding field is the establishment of various transgenic crops, including cotton, corn, rice, tomato etc. In addition, utilization of transgenic plants for the generation of antibodies, gene epitopes and complex proteins has drawn much attention recently. Among these results, the use of plant parts with inducted antigens such as cholera toxin B subunit, toxigenic E. coli LT-B subunit as oral vaccines is attractive as a new route of medication. Considering their effectiveness as vaccines in animal and clinical tests, and simple agricultural practice for large scale production it is anticipated that these antibodies are bound to offer impact to health care for people of the Third World. In this short review, the laboratory and successful clinical test, merits and demerits in comparison with the currently used bioreactors, methods of extraction, and cost estimation of transgenic plant products for medical purposes are briefly reviewed.
Chiao
J S
JS
Shanghai Institute of Plant Physiology and Ecology, Shanghai 200032, China.
D010944:Plants / Q000378:metabolism*; D030821:Plants, Genetically Modified; D011994:Recombinant Proteins / Q000096:biosynthesis*; D014614:Vaccines, Synthetic / Q000276:immunology*
D011994:Recombinant Proteins; D014614:Vaccines, Synthetic